TAPI-0

TAPI-0

• CAS Number: 163958-73-4
• UNSPSC Description: TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. TAPI-0 is a MMP inhibitor and also attenuates TNF-α processing[1][2].
• Target Antigen: Bacterial; MMP; TNF Receptor
• Type: Reference compound
• Related Pathways: Anti-infection;Apoptosis;Metabolic Enzyme/Protease
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/tapi-0.html
• Purity: 98.01
• Solubility: DMSO : 50 mg/mL (ultrasonic)
• Smiles: ONC(C[C@H](C(N[C@H](C(N[C@H](C(N)=O)C)=O)CC1=CC2=C(C=C1)C=CC=C2)=O)CC(C)C)=O
• Molecular Weight: 456.53
• References & Citations: [1]Amit Balakrishnan, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006 Jun 16;281(24):16691-9.|[2]Shiori Haga, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010 Mar;85(3):551-5.
• Shipping Conditions: Blue Ice
• Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
• Clinical Information: No Development Reported